Tifenazoxide

• CAT Number: I012015
• CAS Number: 279215-43-9
• Molecular Formula: C9H10ClN3O2S2
• Molecular Weight: 291.78
• Purity: ≥95%
• IUPAC Name: 6-chloro-N-(1-methylcyclopropyl)-1,1-dioxo-4H-thieno[3,2-e][1,2,4]thiadiazin-3-imine
• InChI: InChI=1S/C9H10ClN3O2S2/c1-9(2-3-9)12-8-11-5-4-6(10)16-7(5)17(14,15)13-8/h4H,2-3H2,1H3,(H2,11,12,13)
• InChIKey: KYSFUHHFTIGRJN-UHFFFAOYSA-N
• SMILES: CC1(CC1)N=C2NC3=C(SC(=C3)Cl)S(=O)(=O)N2

Tifenazoxide (CAT: I012015)) is a potent, orally active, and SUR1/Kir6.2-selective KATP channel opener with strong antidiabetic effects. It suppresses glucose-stimulated insulin release both in vitro and in vivo, thereby improving glucose homeostasis. Tifenazoxide hyperpolarizes β-cell membranes and inhibits insulin secretion from βTC6 cells, rat islets, and human islets with over 100-fold greater potency than diazoxide (IC₅₀ = 0.15 μM; EC₅₀ = 0.45 μM). Unlike diazoxide, it selectively activates Kir6.2/SUR1 but not SUR2-containing channels. In diabetic Zucker rats, oral administration reduces basal hyperglycemia, improves glucose tolerance, lowers hyperinsulinemia, and enhances insulin secretory responsiveness, making it a valuable agent for diabetes research.

Reference

[1]. Carr RD, et al. NN414, a SUR1/Kir6.2-selective potassium channel opener, reduces blood glucose and improves glucose tolerance in the VDF Zucker rat. Diabetes. 2003 Oct;52(10):2513-8.
[Content Brief]

[2]. Hansen JB. Towards selective Kir6.2/SUR1 potassium channel openers, medicinal chemistry and therapeutic perspectives. Curr Med Chem. 2006;13(4):361-76.
[Content Brief]